OutcomesOutcome
Kupperman Menopausal Index total score
1 finding from 1 compound ↓reported in points (total index)
What moved it
How to read these marks1 finding · 1 compound · by evidence strength. No dose is advised.
Kupperman Menopausal Index total score
Findings drawn, by strength
1finding · 1 compound
- Very limited1
Keys
← → round a ring↑ ↓ out and inEnter selecte the outer ringf fit to view+ − zoomEsc clearclick a node to select it
Not pooled · no summary effect · point at a mark · Tab, then the arrow keys
Reported to move it1 finding
- Schisandra chinensisMoved: lowersEvidence: Very limitedPaper: PMID 277638022016
- Who
- Women aged 40 to 70 years complaining of menopausal symptoms on the Kupperman Index; 41 eligible, 36 completed (18 per group); group-by-time analysis over the 12-week follow-up
- Dose studied
- treatment for 6 weeks, followed for 12 weeks; dose not stated in the abstract
Total KI scores were significantly lower in the BMO-30 group than in the placebo group when evaluated with respect to group and time (p = 0.042).”
Quoted verbatim from A randomized, double-blind, placebo-controlled trial of Schisandra chinensis for menopausal symptoms.RCTPermalink
No row matches these filters.
How it is measured
Total score of the Kupperman Menopausal Index (also Kupperman Menopause Index, KMI), the clinician-scored index summing weighted severity ratings of menopausal symptoms (hot flushes and sweating weighted highest, then paraesthesia, insomnia, nervousness, melancholia, vertigo, weakness, arthralgia and myalgia, headache, palpitations, formication) into one total (higher is worse). The version used (11-item original or a modified item set) and the visit at which it was scored are recorded with each finding.
Papers about it
As an endpoint1
Show the paperHide the paper
A randomized, double-blind, placebo-controlled trial of Schisandra chinensis for menopausal symptoms.
Climacteric2016PMID 27763802Via: named in the paper, as read
Sources cited
1 paper